Vilacto Bio (VIBI)

Overall impact
A (80)

Commentary

Vilacto Bio is a leader for overall positive impact. With an 'A' rating of 80.2 for overall impact (94th percentile compared to all companies), Vilacto Bio ranks 49th out of 585 industry peers, behind Amgen, Regeneron Pharmaceuticals, Cell Source and 45 others, and ahead of Grifols, Biogen, Ionis Pharmaceuticals and 533 others. On top material causes for Vilacto Bio's industry (Pharmaceuticals & Biotech), Vilacto Bio performs well in Reduced Use of tobacco (80.5 score), Sustainable Use of Water (95.6), Access to Affordable Healthcare (95.9) and 6 other causes where it received an 'A' score. Vilacto Bio did not receive a 'D' or 'F' rating on any cause.
Impact
Cause VIBI
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
3
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Denmark
Share classes
VIBI
Description
Vilacto Bio Inc. operates as a biotech company in Denmark. The company holds a patented molecule license, known as the Lactoactive molecule, for the treatment of inflammatory diseases, diabetes, psoriasis, and skin issues in various levels. It markets a line of skin care products, including lotions, skin care creams and gels, lip balms, foot creams and oils, and other items through its website, vilacto.com. The company was formerly known as Zlato, Inc. and changed its name to Vilacto Bio Inc. in April 2017. Vilacto Bio Inc. was founded in 2013 and is headquartered in Naestved, Denmark.
Material causes
Ethos considers the following causes material for Vilacto Bio, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.